NASDAQ:VCYT Veracyte (VCYT) Stock Price, News & Analysis → Elon Musk’s Next Move Will Disrupt AI Forever (From InvestorPlace) (Ad) Free VCYT Stock Alerts $22.85 +0.35 (+1.56%) (As of 01:28 PM ET) Add Compare Share Share Today's Range$22.85▼$23.5750-Day Range$18.86▼$22.9552-Week Range$18.61▼$30.52Volume291,315 shsAverage Volume648,848 shsMarket Capitalization$1.75 billionP/E RatioN/ADividend YieldN/APrice Target$27.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Veracyte alerts: Email Address Veracyte MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside17.1% Upside$27.50 Price TargetShort InterestBearish5.74% of Shares Sold ShortDividend StrengthN/ASustainability-1.02Upright™ Environmental ScoreNews Sentiment0.71Based on 19 Articles This WeekInsider TradingSelling Shares$216,500 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.19) to $0.07 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.77 out of 5 starsMedical Sector1275th out of 2,771 stocksMedical Laboratories Industry25th out of 57 stocks 2.3 Analyst's Opinion Consensus RatingVeracyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageVeracyte has only been the subject of 4 research reports in the past 90 days.Read more about Veracyte's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.74% of the outstanding shares of Veracyte have been sold short.Short Interest Ratio / Days to CoverVeracyte has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in Veracyte has recently increased by 20.60%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVeracyte does not currently pay a dividend.Dividend GrowthVeracyte does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreVeracyte has received a 67.11% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Diagnostic test kits", "Management consulting for the pharmaceutical industry", and "DNA sequencers" products. See details.Environmental SustainabilityThe Environmental Impact score for Veracyte is -1.02. Previous Next 2.6 News and Social Media Coverage News SentimentVeracyte has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Veracyte this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for VCYT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Veracyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $216,500.00 in company stock.Percentage Held by InsidersOnly 2.60% of the stock of Veracyte is held by insiders.Read more about Veracyte's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Veracyte are expected to grow in the coming year, from ($0.19) to $0.07 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Veracyte is -24.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Veracyte is -24.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVeracyte has a P/B Ratio of 1.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Veracyte's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyAmerica could fall from this eventAmerica’s “Internal Enemies” Exposed New documentary exposes a hidden election plan in Washington D.C. that, if successful, could be more financially and culturally devastating than the dot-com blowup of 2000, the 2008 financial crisis, or the COVID crash.Click here to see how you can protect yourself today. About Veracyte Stock (NASDAQ:VCYT)Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.Read More VCYT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VCYT Stock News HeadlinesMay 14 at 6:40 AM | americanbankingnews.comVeracyte, Inc. (NASDAQ:VCYT) Short Interest UpdateMay 10, 2024 | markets.businessinsider.comVeracyte’s Robust Performance and Growth Potential Reinforce Buy RatingMay 10, 2024 | markets.businessinsider.comVeracyte’s Strong Q1 Performance and Upbeat Outlook Justify Buy RatingMay 10, 2024 | americanbankingnews.comVeracyte (NASDAQ:VCYT) Given New $27.00 Price Target at Needham & Company LLCMay 9, 2024 | finance.yahoo.comIs Veracyte, Inc. (NASDAQ:VCYT) Trading At A 43% Discount?May 8, 2024 | markets.businessinsider.comMaintaining Buy on Veracyte: Strong Q1 Performance and Progress Toward ProfitabilityMay 8, 2024 | finance.yahoo.comVeracyte, Inc. (NASDAQ:VCYT) Q1 2024 Earnings Call TranscriptMay 8, 2024 | finance.yahoo.comVeracyte Inc (VCYT) (Q1 2024) Earnings Call Transcript Highlights: Strong Start with Revenue ...May 7, 2024 | finance.yahoo.comVeracyte Inc (VCYT) Q1 2024 Earnings: Surpasses Revenue Forecasts with Strong Test PerformanceMay 7, 2024 | seekingalpha.comVeracyte, Inc. 2024 Q1 - Results - Earnings Call PresentationMay 7, 2024 | businesswire.comVeracyte Announces First Quarter 2024 Financial ResultsMay 7, 2024 | markets.businessinsider.comHere's what to expect from Veracyte's earningsMay 6, 2024 | businesswire.com14 Studies Presented at AUA 2024 Show Decipher Tests' Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease UnderstandingMay 5, 2024 | americanbankingnews.comVeracyte (VCYT) Scheduled to Post Quarterly Earnings on TuesdayApril 26, 2024 | bizjournals.comDiagnostics pioneer Bonnie Anderson launches PinkDx to focus on women's healthApril 22, 2024 | businesswire.comVeracyte to Release First Quarter 2024 Financial Results on May 7, 2024April 22, 2024 | finance.yahoo.comNew Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active SurveillanceApril 22, 2024 | businesswire.comNew Study Shows Veracyte's Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active SurveillanceApril 17, 2024 | finance.yahoo.comVeracyte, Inc. (VCYT)April 16, 2024 | businesswire.comVeracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024April 2, 2024 | finance.yahoo.comWhat Makes Veracyte (VCYT) a Lucrative Investment?March 16, 2024 | finance.yahoo.comVCYT Apr 2024 30.000 callFebruary 27, 2024 | businesswire.comVeracyte's Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN GuidelinesFebruary 26, 2024 | investorplace.com7 Under-the-Radar Biotech Stocks Gearing Up for LiftoffFebruary 26, 2024 | markets.businessinsider.comVeracyte’s Strategic Growth and Market Positioning Inspire Positive Analyst OutlookSee More Headlines Receive VCYT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Veracyte and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today5/14/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryN/A Current SymbolNASDAQ:VCYT CUSIPN/A CIK1384101 Webwww.veracyte.com Phone(650) 243-6300Fax650-243-6301Employees815Year Founded2006Price Target and Rating Average Stock Price Target$27.50 High Stock Price Target$34.00 Low Stock Price Target$21.00 Potential Upside/Downside+22.2%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-74,400,000.00 Net Margins-18.16% Pretax Margin-18.76% Return on Equity-1.42% Return on Assets-1.33% Debt Debt-to-Equity RatioN/A Current Ratio5.00 Quick Ratio4.69 Sales & Book Value Annual Sales$361.05 million Price / Sales4.76 Cash Flow$0.10 per share Price / Cash Flow230.25 Book Value$14.30 per share Price / Book1.57Miscellaneous Outstanding Shares76,450,000Free Float74,460,000Market Cap$1.72 billion OptionableOptionable Beta1.65 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Marc A. Stapley (Age 54)CEO & Director Comp: $1.55MMs. Rebecca Chambers (Age 46)Executive VP & CFO Comp: $901.49kDr. Phillip G. Febbo M.D. (Age 58)Chief Scientific & Medical Officer Comp: $657.74kMs. Annie McGuire (Age 43)Executive VP, General Counsel & Chief People Officer Comp: $791.72kDr. John Leite Ph.D. (Age 52)Chief Commercial Officer for CLIA Business Comp: $1.53MMr. Jonathan Wygant (Age 53)VP & Chief Accounting Officer Mr. Steven FrenchSenior VP & Chief Information OfficerMs. Karen PossematoSenior Vice President of Corporate Marketing, Communications & Commercial OperationsMr. Robert Brainin (Age 53)Executive VP & Chief Business Officer Ms. Corinne DananSenior Vice PresidentMore ExecutivesKey CompetitorsViridian TherapeuticsNASDAQ:VRDNGuardant HealthNASDAQ:GHCastle BiosciencesNASDAQ:CSTLFulgent GeneticsNASDAQ:FLGTCareDxNASDAQ:CDNAView All CompetitorsInsiders & InstitutionsCANADA LIFE ASSURANCE CoBought 530 shares on 5/14/2024Ownership: 0.011%Champlain Investment Partners LLCBought 509,340 shares on 5/13/2024Ownership: 3.529%Bessemer Group Inc.Bought 6,940 shares on 5/13/2024Ownership: 0.047%Vanguard Group Inc.Bought 266,660 shares on 5/10/2024Ownership: 9.660%Perkins Capital Management Inc.Sold 1,200 shares on 5/10/2024Ownership: 0.152%View All Insider TransactionsView All Institutional Transactions VCYT Stock Analysis - Frequently Asked Questions Should I buy or sell Veracyte stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" VCYT shares. View VCYT analyst ratings or view top-rated stocks. What is Veracyte's stock price target for 2024? 5 equities research analysts have issued 12 month price objectives for Veracyte's stock. Their VCYT share price targets range from $21.00 to $34.00. On average, they expect the company's share price to reach $27.50 in the next twelve months. This suggests a possible upside of 17.1% from the stock's current price. View analysts price targets for VCYT or view top-rated stocks among Wall Street analysts. How have VCYT shares performed in 2024? Veracyte's stock was trading at $27.51 at the start of the year. Since then, VCYT shares have decreased by 14.6% and is now trading at $23.48. View the best growth stocks for 2024 here. When is Veracyte's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our VCYT earnings forecast. How were Veracyte's earnings last quarter? Veracyte, Inc. (NASDAQ:VCYT) issued its quarterly earnings data on Tuesday, May, 7th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.17. The biotechnology company had revenue of $96.84 million for the quarter, compared to analyst estimates of $93.35 million. Veracyte had a negative trailing twelve-month return on equity of 1.42% and a negative net margin of 18.16%. The firm's revenue was up 17.5% compared to the same quarter last year. During the same quarter last year, the company posted ($0.11) earnings per share. What ETFs hold Veracyte's stock? ETFs with the largest weight of Veracyte (NASDAQ:VCYT) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC), ARK Genomic Revolution ETF (ARKG), Global X Genomics & Biotechnology ETF (GNOM), Invesco Biotechnology & Genome ETF (PBE), ARK Innovation ETF (ARKK), WisdomTree BioRevolution Fund (WDNA) and ARK Next Generation Internation ETF (ARKW).First Trust Nasdaq Lux Digital Health Solutions ETF (EKG). What guidance has Veracyte issued on next quarter's earnings? Veracyte issued an update on its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $402.0 million-$410.0 million, compared to the consensus revenue estimate of $397.8 million. What other stocks do shareholders of Veracyte own? Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), Invitae (NVTA), AbbVie (ABBV), Xtrackers California Municipal Bond ETF (CA), CRISPR Therapeutics (CRSP), Advanced Micro Devices (AMD), Editas Medicine (EDIT), NVIDIA (NVDA), Exelixis (EXEL) and NeoGenomics (NEO). Who are Veracyte's major shareholders? Veracyte's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (9.66%), Sumitomo Mitsui Trust Holdings Inc. (4.46%), Nikko Asset Management Americas Inc. (4.38%), Champlain Investment Partners LLC (3.53%), William Blair Investment Management LLC (0.97%) and Mirae Asset Global Investments Co. Ltd. (0.61%). Insiders that own company stock include Bonnie H Anderson, Evan/ Fa Jones, Giulia C Kennedy, Giulia C Kennedy, Jens Holstein, John L Bishop, Karin Eastham, Marc Stapley and Muna Bhanji. View institutional ownership trends. How do I buy shares of Veracyte? Shares of VCYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Veracyte have any subsidiaries? The following companies are subsidiares of Veracyte: Allegro Diagnostics, Decipher Biosciences Inc., Decipher Corp., Delight Merger Sub II LLC, HalioDx Inc., Veracyte Global B.V., Veracyte International Corp., and Veracyte SAS.Read More This page (NASDAQ:VCYT) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperInvest Now: Starpax's Cancer Breakthrough Achieving What Others Haven't for a CenturyStarpaxDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldThis 1 Biotech Stock has been shocking the marketsHuge AlertsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsREAD THIS – If You Missed Out On The AI BoomBanyan Hill PublishingElon’s New Device is About to Shock the WorldInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veracyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
